Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Leukemia. 2021 Feb;35(2):628-631. doi: 10.1038/s41375-020-0945-3. Epub 2020 Jul 3.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Female
  • Follow-Up Studies
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Hydroxyurea / adverse effects*
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / pathology
  • Prognosis
  • Prospective Studies
  • Retrospective Studies
  • Skin Diseases / chemically induced
  • Skin Diseases / pathology*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • BCR-ABL1 fusion protein, human
  • Fusion Proteins, bcr-abl
  • Hydroxyurea